gefitinib has been researched along with masoprocol in 3 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (masoprocol) | Trials (masoprocol) | Recent Studies (post-2010) (masoprocol) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 138 | 0 | 63 |
5,231 | 566 | 2,919 | 1,527 | 8 | 163 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
Allan, G; Campbell, MJ; Goldfine, ID; Hodges, L; Kerner, JA; Kushner, P; Maddux, BA; Shiry, L; Youngren, JF; Zavodovskaya, M | 1 |
3 other study(ies) available for gefitinib and masoprocol
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gefitinib; Humans; Insulin-Like Growth Factor Binding Protein 3; Masoprocol; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |